• Vaccine Name: BG + MH/DPC
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: The vaccine contains two antigens: the BfrB–GrpE fusion protein and the Mtb10.4–HspX fusion protein from Mycobacterium tuberculosis (Niu et al., 2023).
• bfrB gene engineering:
  • Type: Fusion Protein
  • Description: Use in fusion protein preparation(Niu et al., 2023).
  • Detailed Gene Information: Click Here.
• grpE gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Niu et al., 2023) .
  • Detailed Gene Information: Click Here.
• esxH gene engineering:
  • Type: Fusion Protein
  • Description: This is use in preparation of fusion protein (Niu et al., 2023).
  • Detailed Gene Information: Click Here.
• hspX gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Niu et al., 2023).
  • Detailed Gene Information: Click Here.
• Preservative: Purified BfrB–GrpE and Mtb10.4–HspX fusion proteins were mixed in equal amounts, diluted in PBS, and formulated with DDA, poly(I:C), and cholesterol to produce the BG + MH/DPC vaccine (Niu et al., 2023).
• Immunization Route: subcutaneous injection
• Description: BG + MH/DPC is a fusion protein subunit tuberculosis vaccine that combines BfrB–GrpE and Mtb10.4–HspX antigens in the DPC adjuvant system, resulting in enhanced immune responses and improved protection against Mycobacterium tuberculosis infection (Niu et al., 2023).

Mouse Response

• Host Strain: C57BL/6
• Host gender: female
• Vaccination Protocol: Mice were immunized subcutaneously at weeks 0, 4, and 12 with BG + MH/DPC, receiving 200 µL per dose containing equal amounts of BfrB–GrpE and Mtb10.4–HspX fusion proteins formulated with the DPC adjuvant(Niu et al., 2023).
• Challenge Protocol: Twelve weeks after the final immunization, mice were challenged intravenously with Mycobacterium tuberculosis H37Ra or by aerosol exposure to virulent H37Rv, and bacterial loads in the lungs and spleens were quantified (Niu et al., 2023).
• Efficacy: BG + MH/DPC significantly reduced bacterial burden in the lungs and spleens and provided protective efficacy comparable to BCG vaccination (Niu et al., 2023).
• Information about this animal model: Mouse Model for TB research